Navigation Links
Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
Date:2/26/2009

BLISS-52 and BLISS-76, the ongoing Phase 3 trials of LymphoStat-B (belimumab), are the largest clinical trials ever conducted in lupus patients. HGS expects to report the first Phase 3 data for LymphoStat-B in July 2009 from the BLISS-52 trial, with results from BLISS-76 anticipated in November 2009. LymphoStat-B is being developed by HGS and GSK under a co-development and commercialization agreement entered into in August 2006.

Darapladib: GSK Initiates Phase 3 Development Program

In December 2008, GSK initiated STABILITY, the first Phase 3 clinical trial to evaluate the efficacy and safety of treatment with the investigational Lp-PLA2 inhibitor darapladib to reduce the risk of cardiovascular events in men and women with chronic coronary heart disease. More than 15,000 patients will participate in STABILITY. Darapladib was discovered by GSK based on HGS technology. HGS will receive 10% royalties on worldwide sales if darapladib is commercialized, and has a 20% co-promotion option in North America and Europe.

Syncria(R): GSK Initiates Phase 3 Development; HGS to Receive $9 Million Milestone

In February 2009, GSK announced initiation of a Phase 3 clinical trial program to evaluate the efficacy, safety and tolerability of Syncria (albiglutide) in the long-term treatment of type 2 diabetes mellitus. Syncria is a novel long-acting form of GLP-1 (glucagon-like peptide 1) created by HGS using its proprietary albumin-fusion technology, and licensed to GSK in 2004. HGS is entitled to fees and milestone payments that could amount to as much as $183 million - including $24 million received to date and an additional $9 million milestone payment to be received in the first quarter of 2009. HGS is also entitled to single-digit royalties on worldwide sales if Syncria is commercialized.

CONFERENCE CALL

HGS management
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
2. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
3. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
4. Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs
5. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
6. Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation
7. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
8. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
9. Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
10. 2008 Human Research Protection Award Recipients Announced
11. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Astellas has appointed James Kellerman ... the Americas. Kellerman will report directly to Linda ... Astellas. In his new role, Kellerman will lead a ... and manage the region,s intellectual property matters, coordinating closely ... very pleased to welcome Jim to Astellas. Jim brings ...
(Date:9/2/2014)... Sept. 2, 2014  Numotion is pleased to announce the ... of Directors. Mark is a 30-year retired ... positions across the organization and was a GE Company Officer ... Mark spent many years running business units within GE Healthcare, ... Healthcare Americas. "We are delighted to welcome ...
(Date:9/2/2014)... , Sept. 2, 2014  On July 31, ... to Congress that it is moving forward to regulate ... the minutes until laboratories throughout the U.S. will need ... Although some medical laboratories may subscribe to the ... FDA to put guidelines in place, it,s widely acknowledged ...
Breaking Medicine Technology:Leading Intellectual Property Counsel, James Kellerman, Joins Astellas as Vice President 2FDA Tells Congress It Intends to Regulate LDTs! Web Conference to Provide Straight Talk on Essential Steps Clinical Laboratories and Pathology Groups Will Need to Take to Comply 2FDA Tells Congress It Intends to Regulate LDTs! Web Conference to Provide Straight Talk on Essential Steps Clinical Laboratories and Pathology Groups Will Need to Take to Comply 3
... Solutions Development Company (MSDC), a drug discovery and ... metabolic diseases, announced today that it has launched ... second drug candidate for the treatment of type ... placebo-controlled clinical trial will involve approximately 125 patients ...
... SAN and NYSE: SNY ) announced today ... Rights (CVRs) offered to Genzyme shareholders as part of ... by the U.S. Securities and Exchange Commission. ... Genzyme, sanofi-aventis has commenced an exchange offer to acquire ...
Cached Medicine Technology:Metabolic Solutions Development Company Launches Phase 2a Trial of Its Second Compound to Treat Type 2 Diabetes 2Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective 2Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective 3
(Date:9/2/2014)... Evolve Medical Clinics, the first ... urgent care arena, is having its Grand Opening ... health fair the clinic is sponsoring. Evolve offers ... patients in achieving high quality, convenient medical care. ... is a groundbreaking change in healthcare. The membership ...
(Date:9/2/2014)... September 02, 2014 Last year, SIGVARIS ... with the launch of a luxurious line of graduated compression ... the SEA ISLAND COTTON Socks are joining the SIGVARIS MEDICAL ... more people the comfort of natural cotton fibers. , ... are surprised to find socks as soft as the finest ...
(Date:9/2/2014)... Ticket Down is a reputable source ... September will be an exciting week for soccer fans in ... Ecuador and Bolivia will battle on U.S. soil in friendly ... September 5th - September 9th: , Brazil vs. Ecuador ... Mexico vs. Chile Tickets at Levi's Stadium on ...
(Date:9/2/2014)... 02, 2014 The exclusive ClinicCRM patient ... designed to help doctors manage foreign patient flow, enable ... conversion rates and clink revenue. Since its launch in ... in sales revenue and a 70 percent increase in ... their own healthcare practices. , With its ease of ...
(Date:9/2/2014)... but your outpatient doctor does not know? Or ... care, but your doctor does not have the ... or incomplete communication from hospitals to outpatient primary ... and lead to hospital readmissions. , However, ... improve hospitals, communication during patient care transitions. Researchers ...
Breaking Medicine News(10 mins):Health News:Evolve Medical Clinics Announces Grand Opening of Annapolis, Maryland Location 2Health News:Evolve Medical Clinics Announces Grand Opening of Annapolis, Maryland Location 3Health News:SIGVARIS’ Luxury Line of Compression Socks, SEA ISLAND COTTON, Now Available in Stronger Compression Level 2Health News:Ticket Down Substantially Slashes Ticket Prices on Brazil vs. Ecuador Tickets, Brazil vs. Colombia Tickets, Mexico vs. Chile Tickets and Mexico vs. Bolivia Tickets 2Health News:Ticket Down Substantially Slashes Ticket Prices on Brazil vs. Ecuador Tickets, Brazil vs. Colombia Tickets, Mexico vs. Chile Tickets and Mexico vs. Bolivia Tickets 3Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 2Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 3Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 4Health News:Can data motivate hospital leaders to improve care transitions? 2
... developed countries seem to be becoming ever more hectic. With ... reveals that Australian children in the 10-15 year age ... every nigth when compared with just one generation ago. ... television watching are to blame, with adolescents no longer adhering ...
... alcohol will be introduced in England to ward-off people from ... your limits and drink responsibly will be out by the ... ministers and industry. ,The agreement was first planned ... proper format has been adopted. ,Ministers have insisted ...
... extracted from the blood of bird flu survivors have helped ... virus. ,Scientists have long suspected that culling immune-system ... hard-to-treat H5N1 flu strain. ,If the research pans ... immune system's search-and-destroy force, as an additional way to treat ...
... by an American researcher has revealed that bricks made from ... might be safer than predicted. ,Rather than leach ... bricks do the reverse, pulling minute amounts of the toxic ... Henry Liu, a longtime National Science Foundation (NSF) awardee and ...
... tobacco industry for spreading untruths about smoking in public places ... bans around the world. ,The WHO said ... about the health risks and dangers of second-hand tobacco smoke ... ,"We all know that smoking kills," Shigeru Omi, director of ...
... inflammation are more likely to later develop Alzheimer's disease ... to a study published in the May 29, 2007, ... Academy of Neurology. ,The study, which is ... healthy people with an average age of 79. Blood ...
Cached Medicine News:Health News:Australian Children Sleep Less, Perhaps Not Well Monitored 2Health News:UK Introduce New Health Warnings Against Alcohol 2Health News:Blood from Bird Flu Survivors Provides Breakthrough in Treatment of H5N1 2Health News:Fly Ash Bricks are Absolutely Safer Than Actually Predicted 2Health News:WHO Condemns Tobacco Industry for Misleading Public 2
The Vitatron Pirouet S+ lead series are endocardial leads with extendable/retractable helical screw designed for reliable fixation and optimal pacing characteristics....
Used with permanent pacing leads....
Implantable medical grade silicone end cap for insulation and sealing protection of 5 mm or 3.2 mm connectors....
... the Tupos LV/A+, the single-lead principle has been ... time. The complete system, which consists of the ... minimizes the scope of surgery and the risk ... atrium and the ventricle via a single lead. ...
Medicine Products: